Clinical Trial Update: A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating CLBR001 and SWI019 in autoimmune diseases has been withdrawn from further development.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CLBR001
• SWI019

Snippet

Sponsor: Calibr, a division of Scripps Research | Conditions: Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Status: WITHDRAWN